MRTX-1257 is a novel, potent, selective, orally bioavailable and covalent / irreversible inhibitor of KRAS G12C with an IC50 of 900 pM for KRAS dependent ERK phosphorylation in H358 cells.

MRTX-1133 (MRTX1133; MRTX 1133) is a novel, potent, non-covalent, and selective KRAS G12D inhibitor with antitumor activity.

Antineoplaston A 10 is a Ras inhibitor potentially for the treatment of glioma, lymphoma, astrocytoma and breast cancer.

Sotorasib racemate (AMG-510; AMG510), the racemic mixture of AMG-510, is a novel, potent and covalent inhibitor of KRAS G12C.

Ras-IN-3144 is a novel and potent pan-RAS inhibitor which disrupts the interaction of Ras proteins and their effectors, also inhibits RAS signaling pathways in cancer cells and prevents the growth of RAS mutant mouse cancer xenografts.

Grassofermata (NAV-2729) is a selective ARF6 inhibitor (IC50 = 1.0 μM), or a dual inhibitor of Arf1/Arf6 activation, with anticancer effects.

Exo-1 (Exo1) is a novel, potent and reversible inhibitor of exocytosis which is used as a chemical inhibitor of the exocytic pathway.

BQU57, a derivative of RBC8, is a novel and selective GTPase Ral inhibitor relative to the GTPases Ras and RhoA.

Y16, formerly known as RhoA-IN-Y16, is a RhoA inhibitor, Y16 blocks the binding of LARG, a DBL-family Rho guanine nucleotide exchange factor, with Rho (Kd = 80 nM).

GGTI-298 (GGTI298) is a potent geranylgeranyltransferase-I (GGTase-I) inhibitor with potential anticancer actrivity.